Table 4.

Study list and details – intravenous administration.

Publication	Patient population	Endpoints/definition of CIN	Study type	Sponsor	Procedure	Statistical sample power
Carraro et al. [32]	Patients with mild to moderate CRI	SCr ≥50% 24 h after administration	Prospective, randomized Double-blinded	Investigator	i.v. urography	80% N=64
Chuang et al. [33]	Patients with CRI and/or diabetes	SCr ≥25% 72 h after administration	Prospective, randomized Double-blinded	Investigator	i.v. urography	Not available N=50
Barrett et al. [34]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL and/or SCr ≥25% 2–2 days after administration	Prospective, randomized Double-blinded	Bracco	CT	Not available N=153
Thomsen et al. [35]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL 24, 48 amd 72 h after administration	Prospective, randomized Double-blinded	Bracco	CT	Not available N=184
Nguyen et al. [36]	Patients with moderate to severe CRI	SCr ≥0.5 mg/dL 24, 48 and 72 h after administration	Prospective, randomized Double-blinded	GEHC	CT	95% N=117
Kuhn et al. [37]	Patients with moderate to severe CRI	SCr ≥25% 48–72 h after administration	Prospective, randomized Double-blinded	Bracco	CT	Not available N=248
Zo’o et al. [38]	Pediatric patients (aged 1–16) with normal renal function	SCr ≥0.5 mg/dL 48–72 h after administration	Prospective, randomized Double-blinded	Guerbet	CT	80% N=146